Fierce Pharma

APRIL 8, 2024

With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s (ADC's) reach in the U.S.< | With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s reach in the United States.

FDA 311

FDA 311

MedCity News

APRIL 8, 2024

A new study found that enrollees with zero-premium MA plans are three times as likely to be non-White compared to other MA enrollees and traditional Medicare enrollees. The post Report: How MA Plan Design Affects Utilization, Health Equity appeared first on MedCity News.

Medical 128

Medical 128

Fierce Pharma

APRIL 8, 2024

One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials. | Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found.

FDA 287

FDA Medicine 287

Healthcare Success

APRIL 8, 2024

As an engineering undergrad, I took a Marketing 101 class on a lark, seeking to better understand the psychology behind consumer behavior and developing products with a competitive edge. On the first day of class, we learned the fundamental concept of the 4 Ps of marketing. However, today, I like to use an expanded “7 Ps” definition. In any event, this marketing mix remains essential for any successful marketing strategy.

Marketing 113

Marketing Competition Patients Healthcare 113

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

APRIL 8, 2024

The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump. | The FDA refused to accept Supernus' first approval bid after the company acquired the med in 2020. The following year, the agency doled out a complete response letter, dashing Supernus' second try.

FDA 283

FDA 283

MedCity News

APRIL 8, 2024

Leaders need a framework to identify, understand, effectively address diversity gaps, and measure improvement across the continuum of care. A data-driven approach can provide valuable insights into demographic trends, disparities in healthcare access and outcomes, and the underlying factors contributing to these discrepancies. The post Overcoming Key Diversity Gaps Within the Healthcare Continuum appeared first on MedCity News.

Healthcare 116

Healthcare Healthcare 116

PharmaVoice

APRIL 8, 2024

The market is huge, but will companies overcome the triple hurdles of payer hesitance, prescriber reluctance and sluggish consumer demand?

Doctors 122

Doctors Marketing 122

Fierce Pharma

APRIL 8, 2024

As Pfizer races to grow the respiratory syncytial virus (RSV) vaccine market along with rival GSK, the company has been looking to expand its vaccine's reach. | As Pfizer races to grow the RSV vaccine market along with rival GSK, the company has been looking to expand its vaccine's reach. Now, with fresh data for Abrysvo in adults at higher risk of disease, the New York drugmaker is plotting a new approval filing.

Marketing 167

Marketing 167

PharmaVoice

APRIL 8, 2024

GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to USD 2258.1 million by 2032.

Pharma 106

Pharma Pharmaceutical Marketing 106

Pharmaceutical Commerce

APRIL 8, 2024

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features.

Pharma 105

Pharma 105

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

PharmaVoice

APRIL 8, 2024

Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line. Encouraging more women to partake is a critical step in promoting more equitable healthcare.

Healthcare 106

Healthcare Healthcare 106

pharmaphorum

APRIL 8, 2024

Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels in two studies presented at the American College of Cardiology annual congress. The two companies are racing to bring their apoC-III inhibitors to market for severe hypertriglyceridaemia (HTG) and ultra-rare disorder familial chylomicronaemia syndrome (FCS).

Pharma 107

Pharma Marketing 107

MedCity News

APRIL 8, 2024

The CAR T-therapies Abecma and Carvykti may now be used in earlier lines of treatment for multiple myeloma. The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products. The post Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs appeared first on MedCity News.

FDA 111

FDA Patients Marketing Biopharma 111

European Pharmaceutical Review

APRIL 8, 2024

The first BCMA-targeted CAR-T cell therapy for second-line treatment of multiple myeloma has been approved by the US Food and Drug Administration (FDA). CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) is indicated for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), and are refractory to lenalidomide.

Food and Drug Administration 98

Food and Drug Administration FDA Medicine Physicians 98

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

APRIL 8, 2024

SGLT2 inhibitors have transformed the treatment of heart failure in the last few years, but an attempt to extend their use into the setting of post-heart attack patients has suffered a setback.

Patients 105

Patients 105

MedCity News

APRIL 8, 2024

The FDA expanded Enhertu’s approval to encompass advanced solid tumors positive for the HER2 cancer protein, regardless of tumor type. Analysts say the regulatory decision paves the way for similar broader approvals of other medications in the ADC cancer drug class. The post AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med appeared first on MedCity News.

FDA 106

FDA Medical Biopharma Pharma 106

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

FDA 100

FDA 100

MedCity News

APRIL 8, 2024

UPMC researchers published a study demonstrating the efficacy of Pip Care, a surgical app and healthcare coaching platform. The research showed patients who used Pip Care reduced their hospital stay by nearly a day and cut in half their risk of readmission within a week of surgery compared to those who didn’t. The post Meet The App UPMC Is Using To Slash Surgical Patients’ Readmission Risk by Half appeared first on MedCity News.

Patients 105

Patients Healthcare Healthcare 105

Advertisement

pharmaphorum

APRIL 8, 2024

FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu for all HER2-positive solid tumours, in a first for both the HER2 inhibitor and ADC category.

FDA 106

FDA 106

MedCity News

APRIL 8, 2024

To ward off the worsening economic impact and escalating costs associated with neglected oral health in the U.S., we must work with policymakers and state governments to expand access to routine dental healthcare and improve dental insurance availability and service coverage for all. The post The Price We Pay for Poor Oral Health appeared first on MedCity News.

Insurance 105

Insurance Government Healthcare Healthcare 105

Pharmaceutical Technology

APRIL 8, 2024

The FDA has approved the NDA for SH-201, an oral liquid drug that slows or stops the growth of certain types of leukaemia.

FDA 105

FDA 105

PharmaTimes

APRIL 8, 2024

The project aims to advance therapeutics for tuberculosis, malaria and hepatitis C in LMICs

109

109

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Technology

APRIL 8, 2024

Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma have received FDA approval for relapsed or refractory multiple myeloma (RRMM).

FDA 95

FDA 95

PharmaTimes

APRIL 8, 2024

Around three million people in the UK were estimated to be living with cancer in 2022

Healthcare 104

Healthcare Healthcare Pharmaceutical 104

Pharmaceutical Technology

APRIL 8, 2024

J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma (MM).

FDA 98

FDA Patients 98

Integrity Solutions

APRIL 8, 2024

Sales has always meant navigating highs and lows, dealing with rejection and remaining focused in the face of new business demands and pressures. Lately, though, it’s as if those pressures have been magnified times ten. As the sales environment has grown more complex, one of the biggest challenges salespeople are confronting is an internal one: how to stay self-motivated when sales conversations are harder to come by, buying cycles are only getting longer , buying committees are larger tha

Sales 71

Sales Training Product Knowledge Management 71

Advertisement

Distribution

Pharmaceutical Commerce

APRIL 8, 2024

The latest news for pharma industry insiders.

Pharma 101

Pharma Medical 101

Integrity Solutions

APRIL 8, 2024

Sales has always meant navigating highs and lows, dealing with rejection and remaining focused in the face of new business demands and pressures. Lately, though, it’s as if those pressures have been magnified times ten. As the sales environment has grown more complex, one of the biggest challenges salespeople are confronting is an internal one: how to stay self-motivated when sales conversations are harder to come by, buying cycles are only getting longer , buying committees are larger tha

Sales 60

Sales Training Product Knowledge Management 60

PharmaTech

APRIL 8, 2024

Ensure the success of clinical biomanufacturing programs by focusing on key tech transfer practices from the sponsor, commercial, scientific, and program management stakeholders.

Manufacturing 52

Manufacturing Management 52

PharmExec

APRIL 8, 2024

PIONEER AF-PCI exploratory trial found that elderly patients experienced a lower rate of clinically significant bleeding after 12 months of treatment with Xarelto (rivaroxaban).

Patients 52

Patients 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales